Swiss Rockets Featured in Finanz und Wirtschaft: Strong Industry Recognition and Promising Clinical Outlook

The article, titled “Schweizer Biotechs feiern unerwartet Erfolge”, highlights major advances in the Swiss biotech sector and includes a detailed mention of Swiss Rockets and our subsidiaries, Torqur and Torpedo Pharmaceuticals.

Our CEO, Dr. Vladimir Cmiljanovic, was interviewed regarding the Phase II clinical results of Bimiralisib, our leading compound at Torqur. The study demonstrated a remarkable response in 70% of patients with advanced actinic keratosis, showing complete or near-complete lesion clearance within just four weeks. Additional results for patients in earlier disease stages are expected shortly and may further support the compound’s strong clinical profile.

Dr. Cmiljanovic emphasized that Bimiralisib, if results continue to impress, could capture a significant share of a $10 billion market, potentially outperforming current therapies with fewer side effects. Discussions with several major pharmaceutical companies are ongoing regarding potential partnerships.

The article also mentions that Torpedo Pharmaceuticals’ radioligand therapies have sparked interest from Big Pharma, with partnership negotiations actively in progress.

This recognition in Finanz und Wirtschaft affirms Swiss Rockets’ leadership in next-generation therapeutics and reflects growing momentum in our mission to bring transformative medicines to patients worldwide.

Click here to download the PDF copy of the article.